Combined effects of irbesartan and carvedilol on expression of tissue factor and tissue factor pathway inhibitor in rats after myocardial infarction

Heart and Vessels

Volumn 26, Issue 6, 2011, Pages 646-653

  Yu, Junmin ^a   Zhao, Jiyi ^a   Liu, Wei ^a   Ge, Zhenzhong ^a   Du, Yongli ^b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Tongliao City Hospital   (China)

Author keywords

Carvedilol; Irbesartan; Myocardial infarction; Tissue factor; Tissue factor pathway inhibitor

Indexed keywords

CARVEDILOL; IRBESARTAN; MESSENGER RNA; PLACEBO; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GENE EXPRESSION; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE MASS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADRENERGIC ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BIPHENYL COMPOUNDS; BLOOD COAGULATION; BLOTTING, WESTERN; CARBAZOLES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; DRUG THERAPY, COMBINATION; LIPOPROTEINS; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; PROPANOLAMINES; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TETRAZOLES; THROMBOPLASTIN;

EID: 82655181318     PISSN: 09108327     EISSN: 16152573     Source Type: Journal    
DOI: 10.1007/s00380-010-0106-0     Document Type: Article

References (40)

1. RN Doughty GA Whalley G Gamble S MacMahon N Sharpe 1997 Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group J Am Coll Cardiol 29 1060 1066 9120160 10.1016/S0735- 1097(97)00012-0 1:CAS:528:DyaK2sXislamsbw%3D (Pubitemid 27149582)
2. R Senior S Basu C Kinsey S Schaeffer A Lahiri 1999 Carvedilol prevents remodeling in patients with left ventricular dysfunction after acute myocardial infarction Am Heart J 137 646 652 10097224 10.1016/S0002-8703(99)70217-6 1:STN:280:DyaK1M7pvFSqtg%3D%3D (Pubitemid 29173576)
3. YJ Yang P Zhang YM Ruan 2000 Comparison of losartan, enalapril and their combination in preventing ventricular remodeling after myocardial infarction in rats Eur Heart J 21 Suppl 72
4. YJ Yang YD Tang P Zhang YM Ruan XL Xu YW Zhou Y Tian RL Gao JL Chen ZJ Chen 2001 Effects of different doses of carvedilol for prevention and treatment of left ventricular remodeling in rats with acute myocardial infarction Chin J Med 81 927 930 1:CAS:528:DC%2BD3MXntF2msbo%3D
5. C Richer P Fomes C Cazaubon V Domergue D Nisato JF Giudicelli 1999 Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats Cardiovasc Res 41 100 108 10325957 10.1016/S0008-6363(98)00227-2 1:CAS:528: DyaK1MXmtVKmtA%3D%3D (Pubitemid 29016049)
6. C Fernandes-Santos L Mendonca CA Mandarin-de-Lacerda 2009 Favorable cardiac and aortic remodeling in olmesartan-treated spontaneously hypertensive rats Heart Vessels 24 219 227 19466524 10.1007/s00380-008-1104-3
7. 1 receptor blocker, olmesartan, and estrogen on atherosclerosis via anti-oxidative stress Hypertension 45 545 551 15723967 10.1161/01.HYP.0000157409.88971.fc 1:CAS:528:DC%2BD2MXisVGltL8%3D (Pubitemid 40411257)
8. BA Steppich SL Braun A Stein G Demetz P Groha A Schömig N von Beckerath A Kastrati I Ott 2009 Plasma TF activity predicts cardiovascular mortality in patients with acute myocardial infarction Thromb J 7 11 10.1186/1477-9560-7-11 19570241 10.1186/1477-9560-7-11
9. AG Zaman G Helft SG Worthley JJ Badimon 2000 The role of plaque rupture and thrombosis in coronary artery disease Atherosclerosis 149 251 266 10729375 10.1016/S0021-9150(99)00479-7 1:CAS:528:DC%2BD3cXhvV2ktrs%3D (Pubitemid 30145535)
10. B Steppich C Mattisek D Sobczyk A Kastrati A Schömig I Ott 2005 Tissue factor pathway inhibitor on circulating microparticles in acute myocardial infarction Thromb Haemost 93 35 39 15630488 1:CAS:528: DC%2BD2MXptVynsw%3D%3D (Pubitemid 40124252)
11. KK Koh WJ Chung JY Ahn SH Han WC Kang YH Seo TH Ahn IS Choi EK Shin 2004 Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study Atherosclerosis 177 155 160 15488878 10.1016/j.atherosclerosis.2004.07.008 1:CAS:528:DC%2BD2cXos1ektbc%3D (Pubitemid 39361150)
12. Yang QF, Li CL, Chen J, Liu J, Liu H, Hu FC, Hu YC, Zhang YZ (2003) Effects of carvedilol on blood viscosity and platelet aggregation in patients with essential hypertension. Henan Univ Trans Med Sci Ed 22:20-22
13. RY Zang YH Sun YL Huang 2002 Effects of fosinopril, irbesartan and combined treatment on ventricular remodeling after myocardial infarction Chin J Cardiol 30 10 626 629
14. M Nishiyama IS Park T Yoshikawa Y Hatai M Ando Y Takahashi K Mori Y Murakami 2009 Efficacy and safety of carvedilol for heart failure in children and patients with congenital heart disease Heart Vessels 24 187 192 19466519 10.1007/s00380-008-1102-5
15. MP Schneider AU Klingbeil C Delles M Ludwig RE Kolloch M Krekler KO Stumpe RE Schmieder 2004 Effect of irbesartan versus atenolol on left ventricular mass and voltage: results of the cardiovascular irbesartan project Hypertension 44 61 66 15184349 10.1161/01.HYP.0000133249.28773.d7 1:CAS:528:DC%2BD2cXltVSqtL8%3D (Pubitemid 38823488)
16. N Toda 2003 Vasodilating beta-adrenoceptor blockers as cardiovascular therapeutics Pharmacol Ther 100 215 234 14652111 10.1016/j.pharmthera.2003.09. 001 1:CAS:528:DC%2BD3sXptlylsr4%3D (Pubitemid 37494907)
17. RN Doughty GA Whalley HA Walsh GD Gamble J López-Sendón N Sharpe CAPRICORN Echo Substudy Investigators 2004 Effects of carvedilol on left ventricular remodeling after acute myocardial iinfarction: the CAPRICORN Echo Substudy Circulation 109 201 206 14707020 10.1161/01.CIR.0000108928.25690.94 1:CAS:528:DC%2BD2cXis1eqtg%3D%3D (Pubitemid 38114140)
18. WH Frishman LS Henderson MA Lukas 2008 Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction Vasc Health Risk Manag 4 1387 1400 19337551 1:CAS:528:DC%2BD1MXjtlWgt7g%3D
19. H Wen H Jiang Z Lu B He X Hu J Chen D Zhao 2009 Carvedilol ameliorates the decreases in connexin 43 and ventricular fibrillation threshold in rats with myocardial infarction Tohoku J Exp Med 218 121 127 19478468 10.1620/tjem.218.121 1:CAS:528:DC%2BD1MXosVagtbo%3D
20. D Ardissino PA Merlini R Ariëns R Coppola E Bramucci PM Mannucci 1997 Tissue factor antigen and activity in human coronary atherosclerotic plaques Lancet 349 769 771 9074577 10.1016/S0140-6736(96)11189-2 1:STN:280:DyaK2s3ivVCquw%3D%3D (Pubitemid 27122461)
21. AM Carter 2005 Inflammation, thrombosis and acute coronary syndromes Diab Vasc Dis Res 2 113 121 16334592 10.3132/dvdr.2005.018 (Pubitemid 41695169)
22. P Golino M Ragni P Cirillo A Scognamiglio A Ravera C Buono A Guarino O Piro C Lambiase F Botticella M Ezban M Condorelli M Chiariello 2000 Recombinant human, active site-blocked factor VIIa reduces infarct size and no-reflow phenomenon in rabbits Am J Physiol Heart Circ Physiol 278 H1507 H1516 10775128 1:CAS:528:DC%2BD3cXjvFahsrs%3D
23. JH Erlich EM Boyle J Labriola JC Kovacich RA Santucci C Fearns EN Morgan W Yun T Luther O Kojikawa TR Martin TH Pohlman ED Verrier N Mackman 2000 Inhibition of the tissue factor-thrombin pathway limits infarct size after myocardial ischemia-reperfusion injury by reducing inflammation Am J Pathol 157 1849 1862 11106558 10.1016/S0002-9440(10)64824-9 1:CAS:528: DC%2BD3MXhsVKrsQ%3D%3D
24. E Napoleone A Di Santo M Camera E Tremoli R Lorenzet 2000 Angiotensin converting enzyme inhibitors downregulate tissue factor synthesis in monocytes Circ Res 86 139 143 10666408 1:CAS:528:DC%2BD3cXht1Cksbs%3D (Pubitemid 30086173)
25. DN Muller EM Mervaala F Schmidt JK Park R Dechend E Genersch V Breu BM Löffler D Ganten W Schneider H Haller FC Luft 2000 Effect of bosentan on NF-kappaB, inflammation, and tissue factor in angiotensin II-induced end-organ damage Hypertension 36 282 290 10948091 1:CAS:528:DC%2BD3cXmtlersb8%3D (Pubitemid 30627001)
26. E Napoleone A Di Santo M Camera E Tremoli R Lorenzet 2000 Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes Circ Res 86 139 143 10666408 1:CAS:528:DC%2BD3cXht1Cksbs%3D (Pubitemid 30086173)
27. KK Koh WJ Chung JY Ahn SH Han WC Kang YH Seo TH Ahn IS Choi EK Shin 2004 Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study Atherosclerosis 177 155 160 15488878 10.1016/j.atherosclerosis.2004.07.008 1:CAS:528:DC%2BD2cXos1ektbc%3D (Pubitemid 39361150)
28. N Li W Zhu L Chen Y Ke 2006 Effects of valsartan and captopril on expression and activity of rabbit vascular smooth muscle cell tissue factors and tissue factor pathway inhibitors Chin J Cardiol 34 922 1:CAS:528: DC%2BD28Xht1Ort7jE
29. S Soeda T Tsunoda Y Kurokawa H Shimeno 1998 Tumor necrosis factor-α induced release of plasminogen activator inhibitor-1 from human umbilical vein endothelial cells: involvement of intracellular ceramide signaling event Biochim Biophys Acta 1448 37 45 9824663 10.1016/S0167-4889(98)00112-8 1:CAS:528:DyaK1cXntlyns78%3D (Pubitemid 28526617)
30. M Birgel H Gottschling-Zeller K Röhrig H Hauner 2000 Role of cytokines in the regulation of plasminogen activator inhibitor-1 expression and secretion in newly differentiated subcutaneous human adipocytes Arterioscler Thromb Vasc Biol 20 1682 1687 10845889 10.1161/01.ATV.20.6.1682 1:CAS:528:DC%2BD3cXksVCgtLY%3D (Pubitemid 30353905)
31. L Rössig J Haendeler Z Mallat B Hugel JM Freyssinet A Tedgui S Dimmeler AM Zeiher 2000 Congestive heart failure induces endothelial cell apotosis: protective role of carvedilol J Am Coll Cardiol 36 2081 2089 11127444 10.1016/S0735-1097(00)01002-0
32. T Polte S Oberle H Schder 1997 Nitric oxide protects endothelial cells from tumor necrosis factor-α mediated cytotoxicity: possible involvement of cyclic GMP FEBS Lett 409 46 48 9199501 10.1016/S0014-5793(97)00480-8 1:CAS:528:DyaK2sXjsFyjtbk%3D (Pubitemid 27248564)
33. P Castro JL Vukasovic M Chiong G Díaz-Araya H Alcaino M Copaja R Valenzuela D Greig O Pérez R Corbalan S Lavandero 2005 Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure Eur J Heart Fail 7 1033 1039 16227141 10.1016/j.ejheart.2004.11.009 1:CAS:528:DC%2BD2MXhtFShsrfP (Pubitemid 41443599)
34. S Verma 2004 Angiotensin receptor blockers and myocardial infarction BMJ 329 1248 1249 15564232 10.1136/bmj.329.7477.1248 (Pubitemid 39582781)
35. B Kveiborg A Major-Petersen B Christiansen C Torp-Pedersen 2007 Carvedilol in the treatment of chronic heart failure: lessons from the Carvedilol or Metroprolol European Trial Vasc Health Risk Manag 3 31 37 17583173 1:CAS:528:DC%2BD2sXntVSgtLc%3D (Pubitemid 46860715)
36. McDonald MA, Simpson SH, Ezedowits JA, Gyenes G, Tsuyuki RT (2005) Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ doi: 10.1136/bmj.38595.518542.3A (Pubitemid 41509122)
37. J Wang TB Zhu ZJ Yang LS Wang WZ Ma 2005 Study of free tissue factor pathway inhibitors in acute coronary syndrome Nanjing Med Univ Trans Nat Sci Ed 25 259 261 1:CAS:528:DC%2BD28XhvFyqtLw%3D
38. M Falciani AM Gori S Fedi L Chiarugi I Simonetti RP Dabizzi D Prisco G Pepe R Abbate GF Gensini GG Neri Serneri 1998 Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischemic heart diseases patients Thromb Haemost 79 495 499 9531029 1:CAS:528:DyaK1cXhs1Cisrw%3D (Pubitemid 28120778)
39. Y Wu B Sun Q Dai W Wang 2006 Changes in plasma tissue factor and tissue factor pathway inhibitor levels in patients with acute myocardial infarction undergoing anticoagulant therapy Chin J Med 41 6 35 36
40. H Soejima H Ogawa H Yasue K Kaikita K Nishiyama K Misumi K Takazoe Y Miyao M Yoshimura K Kugiyama S Nakamura I Tsuji K Kumeda 1999 Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina Circulation 22 2908 2913 (Pubitemid 29258979)